CSU HOME THERAPY JUST GOT EASIER
There is great news for patients who suffer from Chronic Spontaneous Urticaria(CSU) in that there is now a new Omalizumab biosimilar that has been approved for NHS use. Enter Omlyclo by CELLTRION Healthcare. I am excited about this biosimilar not because there is anything different in the medication, it is still good old Omalizumab, but because this time thought has been put into patient experience.
Omlyclo Product Image Boxes For Demonstration
CSU patients have always had two options when it comes to how they get to administer their Omalizumab. It can be done at the clinic by the Nurse/healthcare professional, which involves them having to make time outside of work or their daily activities to come into the clinic to get their medication. There is also the option for home therapy, where after training in clinic by a healthcare professional, the patient or their trained carer can administer their medication at home, giving them more flexibility with regards to how they manage their condition, medication and time. In both instances, the pre-filled syringe with needle has been the only option available for use for both hospital treatment and home therapy. This has put off some patients from trying home therapy because of being scared of needles and the idea of prepping the injection before injecting oneself. Thus denying them the flexibility of treatment where they do not have to attend clinics regularly.
Omlyclo comes in pre-filled syringes and also pre-filled pens of 150mg/1.0mL (other strengths are available),and it is the pens that i am excited about because for once it make home therapy easier and more convinient. You can tell that the manufacturing company has taken patient experience into account especially those who would have wanted to go the home therapy route but were put off by the syringe/ needle design. While it still comes in 150mg and not 300mg which is the dose used, meaning one would still have to administer two injections, the pen design is more user friendly and takes away the scary connotations associated with the Syringe/needle design.
One would be forgiven for thinking that this is an ad for Omlyclo, i can assure that it is not an ad but an appreciation for their pre-filled pens which to me are a game changer for patients and their experience with how they navigate their treatment. It is a game changer in Omalizumab administration and patient experience and that can only be a good thing, right?
